Hybrid Imaging for Pancreatic Malignancy

Jha, Priyanka; Bijan, Bijan; Melendres, Giselle; Shelton, David K.

doi:10.1097/rlu.0000000000000677

Cited by 11 publications

(3 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This examination does not differentiate inflammatory changes from malignant tumours because both conditions manifest with increased accumulation of the tracer. As a diagnostic tool, PET-CT is similar to CT and does not bring any further benefits [32, 33].…”

Section: Recommendations On the Diagnostics Of Pancreatic Ductal Adenmentioning

confidence: 99%

Diagnostic and therapeutic recommendations in pancreatic ductal adenocarcinoma. Recommendations of the Working Group of the Polish Pancreatic Club

Winter¹,

Talar-Wojnarowska²,

Dâbrowski³

et al. 2019

View full text Add to dashboard Cite

These recommendations refer to the current management in pancreatic ductal adenocarcinoma (PDAC), a neoplasia characterised by an aggressive course and extremely poor prognosis. The recommendations regard diagnosis, surgical, adjuvant and palliative treatment, with consideration given to endoscopic and surgical methods. A vast majority of the statements are based on data obtained in clinical studies and experts' recommendations on PDAC management, including the following guidelines:

show abstract

Section: Recommendations On the Diagnostics Of Pancreatic Ductal Adenmentioning

confidence: 99%

Diagnostic and therapeutic recommendations in pancreatic ductal adenocarcinoma. Recommendations of the Working Group of the Polish Pancreatic Club

Winter¹,

Talar-Wojnarowska²,

Dâbrowski³

et al. 2019

View full text Add to dashboard Cite

show abstract

“…PET-CT imaging has played an important role in characterizing pancreatic lesions and its metastatic spread. Most malignant tumors of the pancreas are active on FDG PET imaging and PET-CT has much higher sensitivity and specificity than contrast enhanced CT [ 35 ] as illustrated in Figure 5 . MRI is frequently employed to evaluate pancreatic lesions because of its superior soft tissue contrast resolution.…”

Section: Pancreatic Cancermentioning

confidence: 99%

Clinical Utility of Positron Emission Tomography Magnetic Resonance Imaging (PET-MRI) in Gastrointestinal Cancers

Matthews

Choi

2016

Diagnostics

View full text Add to dashboard Cite

Anatomic imaging utilizing both CT (computed tomography) and MRI (magnetic resonance imaging) limits the assessment of cancer metastases in lymph nodes and distant organs while functional imaging like PET (positron emission tomography) scan has its limitation in spatial resolution capacity. Hybrid imaging utilizing PET-CT and PET-MRI are novel imaging modalities that are changing the current landscape in cancer diagnosis, staging, and treatment response. MRI has shown to have higher sensitivity in soft tissue, head and neck pathology, and pelvic disease, as well as, detecting small metastases in the liver and bone compared to CT. Combining MRI with PET allows for detection of metastases that may have been missed with current imaging modalities. In this review, we will examine the clinical utility of FDG PET-MRI in the diagnosis and staging of gastrointestinal cancers with focus on esophageal, stomach, colorectal, and pancreatic cancers. We will also explore its role in treatment response and future directions associated with it.

show abstract

“…In addition, image-guided invasive therapy has the promise to improve outcomes and reduce collateral effects compared to systemic or surgical treatment [ 20 , 21 ]. Hybrid imaging techniques are able to supply complementary information for improved staging and therapy planning [ 22 , 23 , 24 ]. Early detection of cancer through screening based on imaging is probably the major contributor to a reduction in mortality for certain cancers [ 25 ].…”

mentioning

confidence: 99%